Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program
Vassal, G, Cozic, N, Houot, R, Brugières, L, Aparicio, T, Blay, J-Y, Perol, M, Brice, P, Meriaux, E, Geoerger, B, El Bejjani, M R, Moalla, S, Bièche, I, Lantuejoul, S, Mahier Ait Oukhatar, C, Hoog Labouret, N, Moro-Sibilot, D
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
434PBiomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program
Vassal, G, Cozic, N, Houot, R, Brugières, L, Aparicio, T, Blay, J-Y, Perol, M, Brice, P, Meriaux, E, Geoerger, B, El Bejjani, M R, Moalla, S, Bièche, I, Lantuejoul, S, Mahier Ait Oukhatar, C, Hoog Labouret, N, Moro-Sibilot, D
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article